

First in vivo experiences with living, autologous TE heart valves implanted by minimally invasive replacement procedures

Citation for published version (APA):

Dijkman, P. E., Driessen - Mol, A., Stenger, R., Baaijens, F. P. T., & Hoerstrup, S. P. (2007). *First in vivo experiences with living, autologous TE heart valves implanted by minimally invasive replacement procedures*. Poster session presented at Mate Poster Award 2007 : 12th Annual Poster Contest.

Document status and date:

Published: 01/01/2007

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

First *In vivo* Experiences with Living, Autologous TE Heart Valves implanted by Minimally Invasive Replacement Procedures

P.E. Dijkman¹, A. Mol¹, R. Stenger², F.P.T. Baaijens¹, S.P. Hoerstrup^{1,2}

¹ Eindhoven University of Technology, Department of Biomedical Engineering, The Netherlands;

² University Hospital Zurich, Clinic for Cardiovascular Surgery and Department of Surgical Research, Switzerland

Introduction

Minimally invasive valve replacement procedures rapidly evolve as alternative treatment option for patients with valvular heart disease. Tissue engineered heart valves provide a living, autologous valve replacement with the capacity of regeneration and growth, that have shown functionality in chronic animal studies.¹

Aim

The aim of this project was to study the feasibility of combining two promising novel technologies: minimally invasive valve replacement and tissue engineering.




Figure 1: Stented PGA-P4HB scaffold before seeding (A) and TE heart valve before (B) and after (C) implantation.

Materials and methods

Trileaflet heart valves (n=8, Ø30mm) based on rapidly degrading polymer scaffolds (figure 1) and self-expandable stents were engineered from ovine vascular derived autologous cells.




Figure 2: Minimally invasively delivery of the TE heart valve in the pulmonary artery of the sheep. Arrows indicate the stent, that unfolds, after release from the device, by the temperature of the bloodstream.

Valves were seeded with myofibroblasts and grown *in-vitro* for 10 days utilizing diastolic loading bioreactor systems.² Thereafter, valves were seeded with endothelial cells and cultured for 2 more days applying only perfusion. The valves were crimped applying a newly developed introduction system (12mm, figure 3).




Figure 3: Above; Separation of the leaflets and crimping of the TE heart valve. Below; Insertion of the TE heart valve into the implantation device.

Four valves were delivered minimally invasively (mini-thoracotomy, trans-apical approach) in sheep replacing the native pulmonary valves (figure 2). Controls were analyzed directly after the crimping/delivery process for structural integrity. Post-operative follow-up comprised angiography and echocardiography. TE valves were explanted after 4 and 8 weeks. Neo-tissue analyses included histology (figure 4), SEM, ECM quantification and biomechanical testing.




Figure 4: Typical results of H&E staining, Masson trichrome (MT) staining, and von Willebrand factor (vWf) staining of a control leaflet. Sufficient tissue formation is shown (left and middle) as well an endothelial layer on the outflow side of the leaflet (right). (Scalebars represent 200 µm.)

Results

TE heart valves showed preserved structural integrity after the crimping and delivery process. The minimally invasive procedure was successful in all implanted valves and adequate functionality was observed up to 8 weeks. Morphological analyses of the leaflets demonstrated a thickened, layered tissue formation (figure 5) comparable to previous animal studies.² The TE valve ring structures were integrated into the adjacent native tissue after 8 weeks.




Figure 5: Macroscopic photo of explanted valve after 4 weeks. A thickened layered tissue formation on the leaflets is shown by arrows.

Discussion

This *in-vivo* study demonstrates for the first time the successful merging of the two promising heart valve technologies tissue engineering and minimally invasive replacement procedures. Although representing only a preliminary *in vivo* experience, process safety is shown and extended studies are initiated to assess long-term function.